Clinical trials: sponsored by Sarepta Therapeutics, Inc.
Influenza
Safety Study of Single Administration Intravenous Treatment for Influenza
The purpose of this study is to characterize the safety and pharmacology of single administrations of AVI-7100, a candidate treatment for influenza.
- Trial name
- NCT01375985
- Testing
- AVI-7100
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Sarepta Therapeutics, Inc.
Ebola Hemorrhagic Fever
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers
The purpose of this study is to evaluate the safety and tolerability of healthy male and female subjects with intravenous (IV) infusions of AVI 7537 compared to matched placebo in and to evaluate the pharmacokinetics (PK).
- Trial name
- NCT01593072
- Testing
- AVI-7537, Normal Saline Solution (NSS)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sarepta Therapeutics, Inc.
Marburg Hemorrhagic Fever
Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus
The purpose of this study is to characterize the safety and pharmacology of single administrations of AVI-6003, a post-exposure prophylaxis candidate treatment for Marburg virus.
- Trial name
- NCT01353040
- Testing
- AVI-6003
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sarepta Therapeutics, Inc.
Ebola Hemorrhagic Fever
Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus
The purpose of this study is to characterize the safety and pharmacology of single administrations of AVI-6002, a post-exposure prophylaxis candidate treatment for Ebolavirus.
- Trial name
- NCT01353027
- Testing
- AVI-6002
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sarepta Therapeutics, Inc.
West Nile Virus
Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020
During a clinical study of people with severe West Nile virus infections, it was determined that the drug AVI-4020 crossed the blood-brain barrier.
- Trial name
- NCT00387283
- Testing
- AVI-4020 Injection
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Sarepta Therapeutics, Inc.
Cardiovascular Disease, Coronary Artery Bypass
Safety and Efficacy Study of AVI-5126 When Used on Vein Grafts Before Use in Heart by-Pass Graft Surgery (CABG)
For some people who have heart by-pass surgery, the vein that is used to by-pass a blockage will, after some time, become narrowed and possibly blocked.
- Trial name
- NCT00451256
- Testing
- AVI-5126
- Where
- Ukraine
- Volunteers
- 600 people
- Sponsor
- Sarepta Therapeutics, Inc.
West Nile Fever
An Exploratory Study of AVI-4020 in Patients With Possible Acute Neuroinvasive West Nile Virus (WNV) Disease
Although the serious form of West Nile Virus (WNV) disease, referred to as neuroinvasive disease, is rare, it can result in permanent disabilities and occasionally death.
- Trial name
- NCT00091845
- Testing
- AVI-4020 Injection
- Volunteers
- 50 people
- Sponsor
- Sarepta Therapeutics, Inc.
Encephalitis
Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid
AVI-4020 Injection, a phosphorodiamidate Morpholino oligomer (PMO), was found to cross the blood-brain barrier during a study of patients with presumptive West Nile virus disease.
- Trial name
- NCT00381433
- Testing
- AVI-4065 Injection
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Sarepta Therapeutics, Inc.
Neoplasms
Pharmacokinetic Study of a Single Dose of AVI-4126 (RESTEN-NG®) in Cerebral Spinal Fluid
Because AVI-4020 Injection was found to cross the blood-brain barrier, and because AVI-4126 (RESTEN-NG) has potential medical benefit to people with a variety of diseases, including cancers, this study is being performed to find…
- Trial name
- NCT00343148
- Testing
- AVI-4126 Injection (RESTEN-NG®)
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Sarepta Therapeutics, Inc.
Hepatitis C
Study of AVI-4065 in Healthy Volunteers and Chronic Active HCV Patients
Chronic active hepatitis C viral infections are difficult to treat: current drug therapies can result in severe side effects that some patients will not tolerate.
- Trial name
- NCT00229749
- Testing
- AVI-4065 Injection
- Volunteers
- 80 people
- Sponsor
- Sarepta Therapeutics, Inc.
Coronary Artery Disease, Coronary Stent Restenosis
A Phase 1b Study Evaluating RESTEN-MP in Subjects With Focal de Novo Stenosis
The process of re-narrowing of a coronary artery following a revascularization procedure such as angioplasty, begins at the time of the procedure.
- Trial name
- NCT00244647
- Testing
- RESTEN-MP
- Volunteers
- 40 people
- Sponsor
- Sarepta Therapeutics, Inc.
Coronary Artery Disease, Coronary Restenosis
Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries
The process of re-narrowing of a coronary artery following a revascularization procedure such as angioplasty, begins at the time of the procedure.
- Trial name
- NCT00248066
- Testing
- RESTEN-MP
- Where
- 3 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Sarepta Therapeutics, Inc.